Click here to close now.



Welcome!

News Feed Item

Product Launch, Technical Updates, Clinical Study Results, Completion of Tender Offer, and Financial Result - Research Reports on Medtronic, Covidien, Johnson & Johnson, Merck and Jazz

Editor Note: For more information about this release, please scroll to bottom

NEW YORK, August 11, 2014 /PRNewswire/ --


Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Covidien plc (NYSE: COV), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK) and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5626-100free.

--
Medtronic, Inc. Research Reports
On August 1, 2014, Medtronic, Inc. (Medtronic) launched NuVent(TM) EM Sinus Dilation System for the Fusion® ENT Navigation System, developed and manufactured by the Company's Ear Nose and Throat (ENT) division of its Surgical Technologies business. Medtronic informed that NuVent is the first and only balloon sinus dilation system with built-in electromagnetic (EM) surgical navigation technology to help the surgeon confirm anatomy and optimize balloon placement during balloon sinus surgery. Further, the NuVent integrates technology with "plug and play" simplicity through which surgeons can see the precise location of the NuVent instrument's tip on the Fusion screen. Vince Racano, Vice President and General Manager, ENT division, Medtronic, said, "This system is another example of our innovative integration of technologies and therapies that brings Medtronic Surgical Synergy(TM) to the operating room, driving procedural excellence, economic value, and patient care." The full research reports on Medtronic are available to download free of charge at:

http://www.analystsreview.com/Aug-11-2014/MDT/report.pdf

--
Covidien plc Research Reports
On August 6, 2014, Covidien plc's (Covidien) stock declined 2.07% to end the trading session at $84.77, underperforming the Dow Jones Industrial Average (DJIA) that moved up 0.08% over the same trading session. Covidien's stock opened the session at $84.00 and oscillated in the range of $82.38 - $85.06. A total of 13.17 million shares were traded during the day, which is above its 30-day average volume of 5.28 million. Over the past three months, the stock has returned 19.18%, outperforming the DJIA that lost 0.26% over the same period. The full research reports on Covidien are available to download free of charge at:

http://www.analystsreview.com/Aug-11-2014/COV/report.pdf

--
Johnson & Johnson Research Reports
On July 28, 2014, Johnson & Johnson (Johnson & Johnson) reported that the results of the Phase 2 COSMOS (Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) clinical study, published on July 28, 2014 in The Lancet, demonstrated that 92% of genotype 1 chronic hepatitis C virus (HCV) adult patients treated with Janssen R&D Ireland's (Janssen) simeprevir, an NS3/4A protease inhibitor, in combination with sofosbuvir, achieved sustained virologic response 12 weeks after the end of treatment (SVR12), including those patients with compensated cirrhosis and prior null response to treatment with pegylated interferon (PegIFN) and ribavirin (RBV). The Company stated that the open-label, randomised Phase 2 COSMOS study investigated the efficacy and safety of 12 or 24 weeks of simeprevir (150 mg once daily) with sofosbuvir (400 mg once daily) without or with RBV in HCV genotype 1 chronically infected patients with compensated liver disease. The full research reports on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/Aug-11-2014/JNJ/report.pdf

--
Merck & Co., Inc. Research Reports
On August 5, 2014, Merck & Co., Inc. (Merck) announced that it has successfully completed the tender offer to acquire all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (Idenix) at a purchase price of $24.50 per share. Merck informed that as on August 4, 2014, 131.7 million shares of Idenix's common stock were validly tendered and not withdrawn from the offer, representing c.82.5% of the total outstanding common stock of Idenix on a fully diluted basis. Post the completion of tender offer, the Company plans to complete the acquisition of Idenix through a merger of Merck's wholly-owned subsidiary with and into Idenix without stockholder approval. After the completion of merger, Idenix will become a wholly-owned subsidiary of Merck and shares of Idenix will cease to trade on NASDAQ Stock Market. The full research reports on Merck are available to download free of charge at:

http://www.analystsreview.com/Aug-11-2014/MRK/report.pdf

--
Jazz Pharmaceuticals plc Research Reports
On August 5, 2014, Jazz Pharmaceuticals plc (Jazz) reported Q2 2014 total revenues of $291.2 million, up 39.8% YoY, driven primarily by net product sales of Xyrem® (sodium oxybate) oral solution, Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi) and defibrotide, marketed under the name Defitelio® (defibrotide) in Europe. The Company's Q2 2014 net income attributable to Jazz came in at $43.7 million or $0.70 per diluted share, compared to $42.2 million or $0.69 per diluted share in Q2 2013. The Company reported 33.0% YoY growth in its H1 2014 total revenues to $538.1 million, while the net loss attributable to Jazz came in at $49.0 million, compared to net income of $85.6 million in H1 2013. For full-year 2014, the Company expects revenues between $1.1 and $1.2 billion; net product sales between $1.1 and $1.2 billion; and diluted EPS in the range of $0.47 - $0.90. The full research reports on Jazz are available to download free of charge at:

http://www.analystsreview.com/Aug-11-2014/JAZZ/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
The principles behind DevOps are not new - for decades people have been automating system administration and decreasing the time to deploy apps and perform other management tasks. However, only recently did we see the tools and the will necessary to share the benefits and power of automation with a wider circle of people. In his session at DevOps Summit, Bernard Sanders, Chief Technology Officer at CloudBolt Software, explored the latest tools including Puppet, Chef, Docker, and CMPs needed to...
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection.
CIOs and those charged with running IT Operations are challenged to deliver secure, audited, and reliable compute environments for the applications and data for the business. Behind the scenes these tasks are often accomplished by following onerous time-consuming processes and often the management of these environments and processes will be outsourced to multiple IT service providers. In addition, the division of work is often siloed into traditional "towers" that are not well integrated for cro...
Father business cycles and digital consumers are forcing enterprises to respond faster to customer needs and competitive demands. Successful integration of DevOps and Agile development will be key for business success in today’s digital economy. In his session at DevOps Summit, Pradeep Prabhu, Co-Founder & CEO of Cloudmunch, covered the critical practices that enterprises should consider to seamlessly integrate Agile and DevOps processes, barriers to implementing this in the enterprise, and pr...
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
SYS-CON Events announced today that VAI, a leading ERP software provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. VAI (Vormittag Associates, Inc.) is a leading independent mid-market ERP software developer renowned for its flexible solutions and ability to automate critical business functions for the distribution, manufacturing, specialty retail and service sectors. An IBM Premier Business Part...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
Fortunately, meaningful and tangible business cases for IoT are plentiful in a broad array of industries and vertical markets. These range from simple warranty cost reduction for capital intensive assets, to minimizing downtime for vital business tools, to creating feedback loops improving product design, to improving and enhancing enterprise customer experiences. All of these business cases, which will be briefly explored in this session, hinge on cost effectively extracting relevant data from ...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed...
As enterprises work to take advantage of Big Data technologies, they frequently become distracted by product-level decisions. In most new Big Data builds this approach is completely counter-productive: it presupposes tools that may not be a fit for development teams, forces IT to take on the burden of evaluating and maintaining unfamiliar technology, and represents a major up-front expense. In his session at @BigDataExpo at @ThingsExpo, Andrew Warfield, CTO and Co-Founder of Coho Data, will dis...
In most cases, it is convenient to have some human interaction with a web (micro-)service, no matter how small it is. A traditional approach would be to create an HTTP interface, where user requests will be dispatched and HTML/CSS pages must be served. This approach is indeed very traditional for a web site, but not really convenient for a web service, which is not intended to be good looking, 24x7 up and running and UX-optimized. Instead, talking to a web service in a chat-bot mode would be muc...
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies adopt disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advanced analytics, and DevO...